

OUR PIPELINE












We are advancing a **diversified portfolio of product candidates** derived from multiple platforms and are focused on immunotherapies for the potential treatment of cancer and mRNA vaccines to potentially prevent or treat infectious diseases.

Oncology

Drug class	Platform	Product candidate	Indication (target)	Phase 1	Phase 1/2	Phase 2	Phase 3	BioNTech rights ⁽¹⁾	Collaborator/ Partner		
mRNA	FixVac	BNT111	Advanced, R/R melanoma	█	█	█		Fully owned ⁽²⁾			
		BNT113	Metastatic / R/R HPV16+ head and neck cancer	█	█	█					
		BNT116	1L metastatic NSCLC	█	█	█					
	iNeST	BNT122 / RO7198457 (autogene cevumeran)	1L advanced melanoma	█	█	█		Collaboration	Genentech ⁽³⁾		
			Adjuvant colorectal cancer	█	█	█					
			Adjuvant muscle-invasive urothelial carcinoma	█	█	█					
			Adjuvant pancreatic ductal adenocarcinoma	█	█	█					
	RiboMabs	BNT142	Multiple solid tumors (CD3×CLDN6)	█	█		Fully owned				
	RiboCytokines	BNT152 + BNT153	Multiple solid tumors (IL-7, IL-2)	█	█		Fully owned				
	Cell therapies	CAR T cells + CARVac	BNT211	Multiple solid tumors (CLDN6)	█	█		Fully owned			
Neoantigen-based T cells		BNT221	Refractory metastatic melanoma	█	█		Fully owned				
Protein-based therapeutics		BNT311 / GEN1046 (acasnunlimab) ⁽⁴⁾	aPD(L)1-R/R metastatic NSCLC (PD-L1×4-1BB)	█	█	█	█	Collaboration	Genmab		
		BNT312 / GEN1042	Multiple solid tumors (CD40×4-1BB)	█	█	█					
		BNT314 / GEN1059	Multiple solid tumors (EpCAM×4-1BB)	█	█	█					
		BNT315 / GEN1055	Multiple solid tumors (OX40)	█	█	█					
		BNT322 / GEN1056	Multiple solid tumors	█	█	█					
		aPD(L)1-R/R metastatic NSCLC (CTLA-4)	█	█	█	█					
		BNT316 / ONC-392 (gotisobart)	Platinum-resistant ovarian cancer (CTLA-4)	█	█	█				Collaboration	OncoC4
		Metastatic castration-resistant prostate cancer (CTLA-4)	█	█	█						
		Multiple solid tumors (CTLA-4)	█	█	█						
		BNT317	Multiple solid tumors	█	█	█				Fully owned	
	Next-generation immune checkpoint modulators		1L ES-SCLC (PD-L1 x VEGF-A)	█	█	█	█	Fully owned			
			1L Advanced/metastatic TNBC (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█				
			2L SCLC (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█				
			1/2L + ES-SCLC (PD-L1 x VEGF-A)	█	█	█	█				
			1L/2L metastatic TNBC (PD-L1 x VEGF-A)	█	█	█	█				
			1L NSCLC (PD-L1 x VEGF-A) ⁽⁶⁾	█	█	█	█				
			1L ES-SCLC (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█				
			2L ES-SCLC (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█				
			2L neuroendocrine neoplasms (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█				
			1L malignant pleural mesothelioma (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█				
BNT327	1L NSCLC (PD-L1 x VEGF-A) ⁽⁶⁾	█	█	█	█	Fully owned					
1L ES-SCLC (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█							
2L ES-SCLC (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█							
2L neuroendocrine neoplasms (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█							
1L malignant pleural mesothelioma (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█							
EGFRm NSCLC (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█							
1L hepatocellular carcinoma (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█							
Multiple solid tumors (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█							
1L Advanced/metastatic TNBC (PD-L1 x VEGF-A) ⁽⁵⁾	█	█	█	█							
1L hepatocellular carcinoma (PD-L1 x VEGF-A + TIGIT x PVRIG) ⁽⁵⁾	█	█	█	█							
BNT327 + BNT3213	1L hepatocellular carcinoma (PD-L1 x VEGF-A + TIGIT x PVRIG) ⁽⁵⁾	█	█	█	█	Fully owned					
BNT327 + BNT325 / DB-1305	Multiple solid tumors (PD-L1 x VEGF-A + TROP2)	█	█	█	█	Collaboration	Duality Biologics				
BNT323 / DB-1303 (trastuzumab pamirtecant)	HR+ /HER2-low metastatic breast cancer (HER2)	█	█	█	█	Collaboration	Duality Biologics				
Multiple solid tumors (HER2)	█	█	█	█							
BNT324 / DB-1311	Multiple solid tumors (B7-H3)	█	█	█	█						
BNT325 / DB-1305	Multiple solid tumors (TROP2)	█	█	█	█						
BNT326 / YL202	Multiple solid tumors (HER3)	█	█	█	█	Collaboration	MediLink Therapeutics				

⁽¹⁾ For further details about BioNTech's rights, see quarterly reports on BioNTech's website. ⁽²⁾ The FixVac platform is fully owned by BioNTech. The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration. ⁽³⁾ A member of the Roche group. ⁽⁴⁾ Phase 3 development run by Genmab. BioNTech retains a tiered single-digit royalty on any potential sales. ⁽⁵⁾ Trial ongoing in China only. ⁽⁶⁾ Part of a Phase 2/3 clinical trial.

Infectious Diseases

Drug class	Product candidate	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	Commercial	BioNTech rights ⁽¹⁾	Collaborator/ Partner
mRNA	BNT162b2	COVID-19						Collaboration	Pfizer Fosun Pharma
	BNT162b2 + BNT162b4								
	BNT162b2+BNT161	COVID-19 – Influenza combination						Collaboration	Pfizer
	BNT161	Influenza						Collaboration ⁽⁷⁾	Pfizer
	BNT163	HSV						Collaboration	University of Pennsylvania
	BNT164	Tuberculosis	 					Fully owned	Funded by the Gates Foundation
	BNT165	Malaria						Fully owned	
	BNT166	Mpox						Fully owned	Funded by CEPI ⁽⁶⁾
	BNT167	Shingles						Collaboration	Pfizer
	Protein-based therapeutics	BNT331	Bacterial vaginosis						Fully owned

⁽⁷⁾ Out-licensed to Pfizer. ⁽⁶⁾ Coalition for Epidemic Preparedness Innovations.